Pathios Therapeutics Ltd.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pathios Therapeutics Ltd.
Emerging Company Profile: Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing, G protein-coupled receptor 35 with an eye to treating colorectal cancer and other gastrointestinal conditions.
- Site Specific
- Drug Delivery
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.